Restart Life Sciences (TSE:HEAL)
:HEAL
Want to see TSE:HEAL full AI Analyst Report?
Total Valuation
Restart Life Sciences has a market cap or net worth of C$3.47M. The enterprise value is C$3.57M.
Market CapC$3.47M
Enterprise ValueC$3.57M
Share Statistics
Restart Life Sciences has 36,550,354 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding36,550,354
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Restart Life Sciences’s return on equity (ROE) is -1.08 and return on invested capital (ROIC) is -87.79%.
Return on Equity (ROE)-1.08
Return on Assets (ROA)-0.79
Return on Invested Capital (ROIC)-87.79%
Return on Capital Employed (ROCE)-1.05
Revenue Per Employee―
Profits Per Employee-10.00T>
Employee Count―
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Restart Life Sciences is ―. Restart Life Sciences’s PEG ratio is 0.00609.
PE Ratio―
PS Ratio0.00
PB Ratio3.29
Price to Fair Value3.29
Price to FCF-5.91
Price to Operating Cash Flow-2.24
PEG Ratio0.00609
Income Statement
In the last 12 months, Restart Life Sciences had revenue of 0.00 and earned -1.39M in profits. Earnings per share was -0.04.
Revenue0.00
Gross Profit0.00
Operating Income-1.35M
Pretax Income-1.39M
Net Income-1.39M
EBITDA-1.34M
Earnings Per Share (EPS)-0.04
Cash Flow
In the last 12 months, operating cash flow was -638.35K and capital expenditures 0.00, giving a free cash flow of -638.35K billion.
Operating Cash Flow-638.35K
Free Cash Flow-638.35K
Free Cash Flow per Share-0.02
Dividends & Yields
Restart Life Sciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.10
52-Week Price Change90.00%
50-Day Moving Average0.10
200-Day Moving Average0.10
Relative Strength Index (RSI)36.38
Average Volume (3m)3.65K
Important Dates
Restart Life Sciences upcoming earnings date is Jun 2, 2026, TBA (Confirmed).
Last Earnings DateApr 23, 2026
Next Earnings DateJun 2, 2026
Ex-Dividend Date―
Financial Position
Restart Life Sciences as a current ratio of 3.67, with Debt / Equity ratio of 19.06%
Current Ratio3.67
Quick Ratio3.67
Debt to Market Cap0.06
Net Debt to EBITDA1.01
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Restart Life Sciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Restart Life Sciences EV to EBITDA ratio is -2.15, with an EV/FCF ratio of -4.02.
EV to Sales0.00
EV to EBITDA-2.15
EV to Free Cash Flow-4.02
EV to Operating Cash Flow-4.02
Balance Sheet
Restart Life Sciences has C$1.65M in cash and marketable securities with C$245.36K in debt, giving a net cash position of C$1.41M billion.
Cash & Marketable SecuritiesC$1.65M
Total DebtC$245.36K
Net CashC$1.41M
Net Cash Per ShareC$0.04
Tangible Book Value Per ShareC$0.04
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Restart Life Sciences is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast-401.32%